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Abstract
This chapter describes the main deregulated intracellular pathways at both genetic and 
proteomic levels that are found in three main skin cancers: basal cell carcinoma, squa-
mous cell carcinoma and melanoma. In basal cell carcinoma, the main intracellular sig-
naling pathways is the Sonic Hedgehog pathway, while in squamous cell carcinoma, it 
is the p53 pathway. However, in both nonmelanoma skin cancers, these major pathways 
trigger cross-activation with other important ones. In melanoma, mitogen-activated pro-
tein kinase pathway and PI3K/Akt pathways are deeply deregulated, and moreover due 
to the disease complexity, BRAF, RAS (N/H/K), NF1 and Triple-WT melanoma subtypes 
need additional molecular stratification. The stage in which photodynamic therapies’ 
clinical application is in the treatment of these diseases is another subject tackled by the 
chapter. Thus, if basal cell carcinoma and squamous cell carcinoma possess in their thera-
peutical armamentarium photodynamic therapies approach, melanoma, with its particu-
larities, still needs thorough molecular investigations to adapt this particular therapy. 
Based on the accumulated knowledge on pathological intracellular pathways, the chap-
ter describes the molecular details that reside in applying photodynamic therapy. In vivo 
and in vitro models of cutaneous malignancy and photodynamic therapies’ molecular 
events are further detailed.
Keywords: skin cancer, intracellular signaling, biology, photodynamic therapy, 
photosensitizer, proteomics
1. Introduction
Skin cancers, especially cutaneous melanoma, remain a complex therapeutic challenge 
owing to a multiangle problem such as the emergent incidence in white population, the 
inefficiency of classical therapies like surgery and owing to transition to the new wave 
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treatments like targeted therapies, immunotherapy and alternative therapies like photo-
dynamic therapy (PDT). Skin tumors are classified as melanoma and nonmelanoma type. 
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) along with actinic keratosis 
(AK) are considered nonmelanoma skin cancers (NMSC), being the most frequent skin 
cancers in comparison with melanoma which is more rare (only 4%) but highly deadly 
[1]. Similarly, organ transplant recipients (OTR) record an extremely high risk of develop-
ing NMSC [2]. All these types of cancers are generated by complex molecular events that 
favor tumor proliferation and invasion. At the core of this diseases’ pathology intracellular 
pathways deregulation dwell. Therapies that are developed in each cancer type should 
acknowledge the molecular events particularities. In the therapeutical armamentarium 
of skin cancer, PDT has already gained its place. As further presented, the intracellular 
molecular pattern triggered in each type of skin cancer by PDT has both common outlines 
and particularities.
2. Skin cancer, photodynamic therapy and signaling pathways
2.1. Biology of skin cancer in the light of new therapeutical era
Deepening the biology of skin cancer by unraveling the intracellular mechanisms that trigger 
the neoplastic transformation could lead to deciphering new therapy targets and new thera-
peutical approaches. Both cellular and molecular basis of a successful therapy still needs new 
explorations and additional biomedical technologies in order to manage this high morbidity 
and mortality group of diseases.
2.1.1. Basal cell carcinoma
As described in the early 1990 [3], basal cell carcinoma (BCC) is the most common malig-
nancy in humans, and although rarely metastatic, accounts for about two-thirds of all 
skin cancers with a worldwide incidence steady increase [4]. The diversity in the pheno-
typic appearance of BCCs relies on the fact that the majority of BCCs represent monoclonal 
tumors and anatomically distinct BCCs may sometimes share the same cellular origin [5]. 
An extensive genetic study on BCC profiling was published in 2016 investigating around 
300 tumor tissue that displayed the highest mutation rate in cancer (65 mutations per mega 
base). About 85% of all tumors have mutations in the Sonic Hedgehog (Hh) pathway. These 
genes are PTCH1, SMO, SUFU and TP53. Other mutations were found in MYCN, PPP6C, 
STK19, LATS1, ERBB2, PIK3CA and NRAS. Loss-of-function and deleterious missense muta-
tions were found in PTPN14, RB1 and FBXW7 genes [6]. Moreover, 2016 studies have shown 
that genetic predisposition in familial BCC has the most commonly gene mutated, PTCH1, 
main player in the Hh pathway. Another gene associated with familial BCC is SUFU being 
involved in the same pathway. This gene is loosing its function and hence inducing BCC 
predisposition. Understanding the deregulated genes that trigger BCCs can lead to new tar-
geted therapy trials [7]. In the last five years, studies on the biology of BCC have shown that 
Hh pathway is deeply involved in the initiation of this skin tumor. This pathway  cross-talks 
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with other main intracellular pathways involved in skin’s homeostasis. Hence, Wnt path-
way was found as having increased levels of beta-catenin, a critical mediator of Wnt signal-
ing in BCCs [8, 9]. Another important pathway involved in BCC is EGFR/MEK/ERK that 
modulates GLI-dependent transcription in human keratinocytes and drives their oncogenic 
transformation [10, 11]. As epithelial-stromal interactions are creating a protumoral micro-
environment, stromal cells isolated from BCCs, have high levels of gremlin 1. This protein 
antagonizes with the prodifferentiation factors BMP2 and BMP4, sustaining, therefore, 
tumor proliferation [12]. If Hh pathway is deregulated at gene and protein level, another 
deregulated pathway in BCC is the MEK-ERK pathway. Hence, acknowledging that IL-17 
(IL-17A) sustains a chronic inflammatory microenvironment with protumoral consequences 
some important reports were published in 2015. IL-17 binding to its receptor activates the 
route IL-17R-Act1-TRAF4-MEKK3-ERK5 that directly stimulates keratinocyte proliferation 
and tumor formation. In the BCC context, this axis sustains the expression of Steap4-p63 
through p63-mediated TRAF4 expression that directly enhances keratinocyte proliferation 
and further tumor formation [13].
2.1.2. Squamous cell carcinoma
Cutaneous squamous cell carcinoma (SCC) is the second most common human skin malig-
nancy after BCC, and opposed to BCC, it can trigger metastasis. SCC originates the prema-
lign lesions actinic keratosis (AK) and it develops from keratinocytes of the spinous layer. 
The progression of AK to malignancy relies on the sequential DNA mutations in oncogenes 
and tumor suppressor genes. This multistep process triggered by chronic UV irradiation 
leads to increased genomic instability and loss of cell cycle control, thus driving the malig-
nant uncontrolled proliferation of keratinocytes. Details of the molecular pathogenesis of 
SCC are still a subject of intense research [14]. Intracellular signaling deregulated path-
ways in SCC pinpoint to p53 pathway as mutated p53 is the most common genetic abnor-
mality found in SCC. AK lesions can harbor mutated p53, and remain as such through 
the malignization process toward SCC [15, 16]. Whole transcriptome analysis published 
in 2016 has shown in SCC cancer cells, in comparison to normal human epidermal kerati-
nocytes, an overexpression of long intergenic non coding RNA (LINC00162). LINC00162 
is upregulated by the inhibition of the p38α and p38δ mitogen-activated protein kinases. 
Knockdown of LINC00162 inhibited proliferation and migration of SCC cells in vitro and 
inhibited extracellular signal-regulated kinase 1/2 activity, up regulating dual specificity 
phosphatase 6 (DUSP6) [17]. Other, recently published molecules involved in the com-
plex biology of SCC are Ets2 and Elk3 genes, required for malignant progression from 
AK lesions to SCC. ETS2-overactivation in epidermal cancer stem cells induces hyperp-
roliferation and SCC superenhancer-associated genes Fos, Junb and Klf5 expression [18]. 
Epidermal cancer stem cells are characterized by alterations in keratinocyte stem cells 
(KSC) and survivin gene expression. Silencing survivin reduces the classical expression of 
stem cell markers (OCT4, NOTCH1, CD133 and β₁-integrin), and increases differentiation 
markers (K10 and involucrin). Recently published results indicate survivin as a key gene 
in SCC development [19]. Another recently published protein, involved in SCC, is S100A8, 
whose overexpression regulates SCC differentiation [20].
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2.1.3. Cutaneous melanoma
Cutaneous melanoma is one of the solid tumors that bear the highest rate of mutations. In 
2015, The Cancer Genome Atlas Network has proposed a new genomic classification of these 
tumors divided into genomic subtypes: BRAF, RAS (N/H/K), NF1 and Triple-WT [21]. These 
subtypes have significant intracellular pathways deregulations. A BRAF mutation is pres-
ent in the majority of melanomas, and an NRAS isoform is present in 15–30% of melanomas 
[22]. The mitogen-activated protein kinase (MAPK) pathway (Ras/Raf/MEK/ERK pathway) 
has several mutated points so that uncontrolled cellular proliferation may occur [23, 24]. 
Alike to the MAPK pathway, the PI3K/Akt pathway can also be activated by Ras. Once this 
pathway is activated, cell proliferation and invasion are promoted. Although PI3K mutations 
are believed to be rare, downstream components of the PI3K/Akt pathway steadily increase 
during melanoma progression, and are altered in 50–60% of melanomas [25]. CDKN2A is 
another gene that encodes proteins involved in cell cycle regulation. Approximately 10% of 
all melanomas have a familial susceptibility linked to the CDKN2A gene. Somatic CDKN2A 
mutations have been reported in 30–70% of sporadic melanomas [25].
The pathophysiology of each skin cancer can have different gene/protein/intracellular signal-
ing foundation or can share the same molecular pathways. Figure 1 resumes the main intra-
cellular pathways that trigger the three main skin cancers in humans.
2.2. PDT in the clinical management of skin cancers
Owing to a constantly increasing incidence, malignant skin tumors need a multidisciplinary 
approach regarding their clinical management, comprising specialists and therapeutical lines, 
which could be personalized for every situation [26]. In this context, PDT is involved in the 
management of nonmelanoma skin cancers, primary superficial BCCs, low-risk nodular BCCs 
and superficial SCCs [27]. In recent years, even for melanoma, PDT starts to be considered as 
an alternative treatment option.
2.2.1. PDT in BCC therapy
Predominantly located in head and neck region, there are three types of BCC: nodular, super-
ficial and morpheic with an increased heterogeneity [28, 29]. Due to this heterogeneity, there 
Figure 1. Intracellular signaling pathways that characterize the main skin cancer types: basal cell carcinoma (BCC), 
squamous cell carcinoma (SCC) and melanoma.
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are several therapy lines and several ongoing clinical trials that are thoroughly resumed in 
Ref. [10]. Among all these therapies, PDT gains its place. Thus, topical PDT with methyl ester-
based photosensitizer (PS) is currently accepted for superficial BCC. Accordingly, 16% methyl 
ester methyl aminolevulinate (MAL) is approved for topical PDT of BCC in Europe (Metvix®) 
while in the USA the corresponding approved drug is Levulan® (20% of 5-aminolevulinic 
acid in ethanol solution) [28]. The clinical response for PDT in BCC is not clear-cut. Thus 
evaluating more than 130 patients treated with MAL-PDT the best response was obtained for 
superficial BCC (82%) compared to nodular BCC (only 33%). Analyzing the subtypes some 
predictor factors emerged, nodular infiltrative histotypes, ulceration tumor thickness and 
localization on limbs were the negative ones [30]. Trying to improve the clinical outcome, 
two-fold illumination scheme for aminolevulinic acid-photodynamic therapy (ALA-PDT) 
was investigated and one-year post-treatment clinical evolution was assessed. For small BCC 
located outside the head and neck area, this activation scheme has proven good clinical out-
come [31]. For a three-year follow-up in patients treated with MAL-PDT, fluorouracil and 
MAL-PDT have proven the same efficacy in the treatment of superficial BCCs [32].
2.2.2. PDT in SCC therapy
SCC and AK represent the same skin disease but in different stages of evolution, as AK is 
superficial, SCC involves also the dermis. Local PDT is suitable for AK and for in situ SCC 
[33]. Therapeutical protocols in SCC implies surgery (cryosurgery, electrosurgery and radio-
therapy), topical treatments with 5-fluorouracil and imiquimod or PDT [34], successful ALA-
PDT and blue light being reported several years ago [35]. In this type of cancer, although, 
surgical excision is the first therapeutical choice, PDT is a noninvasive approach and it can 
provide optimum cosmetic outcomes. As in SCC, resistant or recurrent tumors can appear, 
and PDT should be combined with other therapeutic modalities. Hence PDT can be com-
bined with immunomodulatory (Imiquimod) and/or chemotherapeutic agents (5-fluoroura-
cil, methotrexate, diclofenac or ingenol mebutate), and/or inhibitors of molecules involved in 
tumorigenesis, such as COX2 or MAPK [36].
2.2.3. PDT in melanoma therapy
There is an interesting link between melanoma patients and the subsequent appearance of 
BCC or SCC. In a study published in 2016, the associations between melanoma diagnosis and 
SCC were studied. The study showed a clear correlation between age, sex, skin characteristics, 
sun exposure and the existence of p.R163Q/p.D294H MC1R variants in melanoma patients, 
parameters that favor the risk of developing a SCC. This study has shown that melanoma 
patients with increased risk of developing another skin cancer should be further stratified [37].
Although in cutaneous melanoma targeted immune-therapies are the best clinical option, 
there is a therapeutical niche for PDT with second generation PS, especially as postsurgery 
adjuvant treatment or even as a preventive approach [38]. PDT exerts specific effects in mel-
anoma cells both upon melanocytic antioxidant system and multidrug resistance cellular 
machinery decreasing these functions essential for melanoma survival. While successful 
in other skin cancers, PDT is not effective in pigmented melanoma due to photophysical 
properties of melanin from melanocyte-transformed cells, as melanin absorbs light over the 
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entire wavelength region used by PS for PDT (400–750 nm). Amelanotic melanoma with 
low melanin pigment load has been more approached in PDT studies [38]. Still only few 
studies are reported in this topic, and clinically there are some promising results for PDT 
with chlorin e(6) in skin metastases [39] and ocular choroidal melanomas [40, 41]. PDT 
with verteporfin alone or in combination with bevacizumab may be useful as primary or 
preoperative procedure for ocular melanoma. There are also recent experimental studies 
involving amelanotic melanoma, the nonpigmented melanoma type owned to a poor dif-
ferentiation of melanocytes, which produce less melanin, refractive to classic treatments 
and for which alternative therapies are taking into account [42]. Thus, in a mouse C57/BL6 
model bearing B78H1 amelanotic melanoma, it was tested a novel PS assembly comprising 
a Zn(II)-phthalocyanine, a polyethylene glycol (PEG) derivative and gold nanoparticles. The 
deposition of PEG on the nanoparticle surface makes the conjugate hydrosoluble prolonging 
the retaining in serum, improving thus the PDT efficacy. The nanoparticle conjugates were 
significantly accumulated and retained in the tumor 3 h postinjection followed by PDT. The 
experimental approach lead to 40% survival of the treated mice, without tumor relapses. 
These types of PS functionalized with nanoparticles have good potential in PDT for difficult 
to treat cancers such as amelanotic melanoma [43]. Another strategy is to use natural com-
pounds as PS in PDT of skin cancer; hence, positive results were obtained with hypericin in 
human melanoma cells, Where an inhibition of proliferation was registered [44]. In addition, 
natural compounds are “back in fashion” and hypericin was tested also in NMSC treatment 
approaches.
2.3. Specific intracellular networks triggered by PDT in skin tumor cells
PDT is an alternative therapy for some type of cancers and several nonmalignant diseases, 
involving application and preferentially accumulation of a PS in the target cell/tissue, fol-
lowed by PS photoactivation with a light wavelength fitting the compound’s absorption. The 
actual effect of PDT depends on many factors but the cell/tissue where the PS is accumulating 
triggers the main process (Figure 2).
Typically the structure of many PSs is based on the tetrapyrrole ring—porphyrins and 
phthalocyanines, including their derivatives (porphycenes)—or natural products such as 
hypericin, riboflavin or curcumin [45]. Several conditions should be attained by a potential 
PS, namely: chemical purity, stability, high solubility in water, preferentially loading in the 
target cell/tissue, low “dark” toxicity and high quantum yield of singlet oxygen (1O
2
) gen-
erated upon photoactivation [45]. This light activation causes the transition of PS first in a 
short-lived excited state then in a long-lived energetic state triggering reactive oxygen spe-
cies (ROS) as main agents of tumor vasculature damage, immune response generation and 
further tumor eradication [46, 47]. Among relatively innovative approaches in skin tumors 
treatment, especially in NMSC, PDT could reveal new lines in terms of novel PSs embossing 
different insights in key intracellular pathways influenced by the PDT treatment. Elucidation 
of mechanisms in PDT has gained advance within the last decade, data regarding signaling 
pathways, transcription factors related to cell cycle control, inflammation and cellular death 
accumulated lately. Nevertheless in a living cell, all these processes are deeply overlapped so 
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minute understanding should be proceeded step by step [48]. Furthermore, survival mecha-
nisms are activated in PDT-treated cells and some transcription factors have been identified 
to be involved in cell resistance following PDT, such as AP-1 transcription factor family mem-
bers, NRF2, hypoxia-inducible factor-1 alpha (HIF-1), nuclear factor-kappa B (NF-κB), HSF1 
and unfolded protein response (UPR) protein group [47]. Involvement of a certain signaling 
pathway could define the response of a treatment. For instance PDT with ALA as PS has been 
widely used to treat SCC. However, a segment of SCC patients does not respond well to this 
PDT therapy, the lack of efficacy being evoked at molecular level by the MAPK signaling 
pathway. In vitro studies on SCL-1 human squamous carcinoma cell line revealed that adding 
inhibitors of MAPK on ALA-treated SCL-1 cells could augment the cytotoxic effects of ALA-
PDT. More specific, the addition of inhibitors for key components belonging MAPK, namely 
ERK1/2, p38 and JNK, induced a more dramatic decrease on cellular viability than induced 
with ALA-PDT alone [49].
Figure 2. PDT effect inflicted upon localization in different cells and tissues. Regardless of the localization there is an 
overall antitumoral effect.
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Figure 3 resumes intracellular events triggered by PDT in cells that were uptaking PS.
2.3.1. Pathways in intracellular events triggered by various photosensitizers used in PDT
As a general picture, in skin cancers, the PDT is a topic procedure, especially applied for 
NMSC while for melanoma could be an adjuvant postsurgery alternative. As PS used in der-
matopathology, only two of them are known to be approved by FDA, namely 5-ALA and 
MAL, which are prodrugs becoming active upon intracellular metabolization [50], while other 
PS attempts are currently made with novel (bio) structures related to porphyrin skeleton such 
as porphycenes [51, 52]. Once activated in tumor cell, a PS triggers different pathways depend-
ing on intracellular localization of PS, PS’s dose and type, light dose, cell genotype, affecting 
cell fate in terms of death and proliferation. PDT triggers the death of cellular target, occurred 
primarily by apoptosis, necrosis and, as recently shown, by autophagy [47]. The PS genera-
Figure 3. Intracellular events triggered by PDT in cells that were uptaking PS. PDT is inflicting upon cellular membrane 
an activation of procaspase 8 to caspase 8 that activates the proapoptotic Bcl family of proteins (Bax, Bid, Bad, Bik and 
Bim). PDT acting on mitochondria induces Bcl-2 that further induces cytochrome C (Cyt C) to form the apoptosome that 
comprises Procaspase 9, APAF-1, cytochrome C and dATP; the result is the formation of active caspase 9 that through 
caspase 3 activates intra-nuclear endonucleases and induces hence DNA fragmentation. When PDT acts on lysosomes 
the cathepsin activation induces activation of caspase 9 with the same fate of DNA fragmentation. When PDT acts on 
the endoplasmic reticulum it induces Ca2+ increase that acts upon the mitochondria to generate Bcl-2 family. PDT can 
activate directly p53 that will act upon mitochondria and upon caspase 9 activation. The overall effect is the cell death in 
PDT-treated cells by apoptotic mechanisms.
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tions evolve continuously, hence from the first generation of PS, Photofrin, a partially purified 
form of hematoporphyrin derivative [53], the second generation was developed to overcome 
disadvantages of the first one, such as tetrapyrrole rings, substituted derivatives of porphy-
rin, chlorin and bacteriochlorin [54]. Recently the newer, third generation of PSs was put in 
scene in novel chemical compounds (e.g. fullerenes) or novel platforms such as PS coupled on 
different carriers [47]. Nowadays, a so called targeted PDT has emerged and in this type of 
therapy, antibodies, peptides, proteins, liposomes, cholesterol or other ligands are coupled to 
PS displaying an improved selective accumulation in the tumor [55].
An advanced generation of PS is always defined by longer wavelengths of light (as red as pos-
sible) which corroborates with a deeper penetration of target tissues and a decreased photo-
sensitivity [56]. The antitumor PDT addresses two important issues: direct harmful effects on 
target cells and vascular injury that will limit blood and other nutrients supply to the affected 
region [57]. There are mainly two ways of cell fate following PDT: cellular death or cellular 
survival. The border between these two opposite processes is fine-lined by specific intracel-
lular mechanisms development.
2.3.1.1. Cellular death induced by PDT
Once inside the target cell subjected to photoactivation, a variety of intracellular pathways are 
initiated by the PS. Although at first sight these biochemical pathways look complex, over-
lapped, multiple and hard to decipher, the target cell will act in one main direction, namely 
survival as a response to PDT-triggered aggression.
Generation of reactive oxygen species upon PDT: The first molecular steps in ROS generation are 
related to PSs’ chemistry, depending on oxygen supply in the target tissue [58], and comprise 
the generation of ROS, as main tools for tumor/target cell destruction. Under the specific light 
action, the PS will absorb a photon moving from a low energetically short-lived singlet state to 
an excited long-lived triplet state able to react with molecular oxygen to produce superoxide 
anion O
2
•− (low reactivity, long lifetime—type I reaction) or singlet oxygen 1O
2
 (high reactiv-
ity, short lifetime—type II reaction) [59].
What is the fate of ROS in photosensitized cells? Different types of ROS inflict different actions. 
Singlet oxygen being highly reactive but evanescent, will oxidize various many biomolecules 
(lipids, nucleic acids, proteins, etc.) at the level of their electron-dense regions [57, 60], while 
superoxide anion due to its low reactivity on direct biological target, will act mainly as a pre-
cursor for other reactive species (e.g. H
2
O
2
 or •OH) that will cause cellular fatal injuries trig-
gering cell death through necrosis or apoptosis [61]. Also it is important to notice that since 
singlet oxygen is a short-lived species, will act immediately upon intracellular targets close to 
the site where PS was accumulated, influencing thus the type of response upon intracellular 
localization [57]. Regardless of ROS type, the outcome is tumor cell eradication by different 
mechanisms of cytotoxicity operated by PDT [46].
Cellular toxicity induced by reactive oxygen species: Three cytotoxicity modes are induced post-
PDT: oxidative stress, hypoxia and antitumor immune response. Oxidative stress it’s installed 
when generated ROS oxidize and irreversible damages nucleic acids (DNA and RNA) [62, 63], 
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lipids [64] and proteins [65] with consequences upon the whole cellular physiology. Certain 
particular changes are related to cellular membrane where phospholipid peroxidation leads 
to alterations of membrane fluidity, permeability and the (photo)oxidation of cellular mem-
brane contributing strongly to cell death [66, 67]. Oxidative stress is linked to locally induced 
hypoxia in the photosensitized tissue, which abort the ATP production by oxidative phos-
phorylation [68] thus leading to cellular death (namely necrosis, an ATP-independent pro-
cess), and further to the antitumor immune response initiation which is the decisive piece for 
complete removal of photodamaged tissue [69]. Upon PDT-induced cellular death, namely 
apoptosis, necrosis, necroptosis [70] and/or autophagy [71]), intracellular damage-associated 
molecular patterns (DAMPs) [72] and tumor-associated antigens (TAAs) are released from the 
photosensitized cells and subsequently trigger an immune response aimed at removing the 
PDT-treated tumor [73].
2.3.1.2. Activation of intracellular survival pathways in photodynamic action
Although cellular death conducted by ROS is envisaged, tumor cells subjected to PDT could 
encounter this stress by triggering survival mechanisms when vascular shutdown was not 
completed following PDT action. This type of response is primarily mediated by several path-
ways raising in an interconnected manner where beside classical NF-kB-mediated proinflam-
matory and proangiogenic activity, is raising also a NRF2-mediated antioxidant response, a 
HIF-1-mediated hypoxia survival, a proteotoxic stress response interceded by certain tran-
scription factors (HSF1, XBP1, ATF6 and ATF4) corroborated with an acute stress reply where 
factors from MAPK pathway are being involved. As PDT means an oxidative stress upon tar-
get cells, many studies related to signaling pathways were treated through the prism of oxida-
tive stress and therefore extrapolated to PDT. Consequently, recent works refer to signaling 
pathways in PDT as to signaling pathways activated in cells subjected to oxidative stress [74].
NRF2 is the main transcription factor protecting against the oxidative stress by restoring the 
intracellular redox balance in a post-PDT–treated cell, promoting the transcription of the genes 
encoding for antioxidant enzymes, antioxidant proteins as well as for multidrug response pro-
teins. Moreover, NRF2 is likely constitutively active in many cancer types potentially desensi-
tizing these cells to PDT effects, mediated by ROS. Cells from various layers of the skin benefit 
from NRF2 protective actions, both in abnormal differentiation, wound healing and control-
ling inflammation. Thus in keratinocytes and melanocytes, NRF2 protects against mutation 
during keratinization and melanogenesis. Also, in fibroblasts, NRF2 protects against differen-
tiation and fibrosis processes; therefore, NRF2 activity could be modulated in the context of 
skin diseases pharmacotherapy and in PDT in order to improve the PDT efficacy by impairing 
adaptation of target cells to oxidative stress. In addition, NRF2 could be a key biomolecule in 
the searching for new drugs for various skin disorders including vitiligo or even cutaneous 
melanoma [75].
NF-κB is a family of transcription factors with a crucial role in inflammation, apoptosis, innate 
immunity and also in cancer initiation. NF-kB interferes with an ample array of signaling 
pathways, including HIF-1, and certain biomolecules such as ROS [76]. The NF-κB activation 
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following PDT could initiate the survival of tumor cells by inhibiting apoptosis and facilitat-
ing angiogenesis. Also, NF-κB pathway could display equally antitumor and protumor func-
tions in different carcinogenesis processes, for instance in epidermal keratinocytes, NF-κB 
seems to exert mainly tumor growth inhibitory functions [77]. In melanoma, the NF-κB activ-
ity in tumorigenesis was demonstrated in a mouse model where HR as-mediated tumorigen-
esis onset relies on IKK2-mediated NF-κB activation [78].
HIF-1 is the central modulating pathway for hypoxic conditions in most tumor cells, as well as 
skin cancers, condition in which it is constitutively activated [79]. Thus, in a hypoxic or even 
anoxic milieu, HIF-1 becomes hyperactivate as a part of survival actions adopted post-PDT [80].
The ASK1 pathway directs the immediate early stress response, namely the rapid transcrip-
tion of a set of genes encoding for stress adapting proteins. Classical ASK1 sends its signal via 
MAPKs proteins to the AP-1 transcription factors responsible for the rapid induction of imme-
diate early gene transcription. Nevertheless, the direct ASK1 activation post-PDT is still diffi-
cult to demonstrate, so the actual involvement of ASK1 in PDT response can only be assumed 
from the effects on downstream kinases (MAPKs) and other transcription factors. This kind of 
indirect proof was reported in a model of PDT with murine PAM212 keratinocytes loaded with 
a benzoporphyrin derivative, where the activation of JNK and p38MAPK were associated with 
early stress response mediated by ASK1. In addition, the early survival response upon PDT 
means a transient JNK and p38MAPK activation triggered by AP-1 transcription factors phos-
phorylation from ASK-1 pathway. Thus, an approach for improving PDT efficacy could be the 
AP-1 pharmacological suppressing while preserving the JNK and p38MAPK functions [81].
The proteotoxic stress response arises as well as a survival mechanism in PDT stressed cells 
triggering certain transcriptional level responses known as the unfolded protein response 
(UPR), a form of endoplasmic reticulum (ER) stress. These resulted unfolded proteins acti-
vate further HSF transcription factors by which an adaptive response comprising chaperones 
upregulated and protein synthesis inhibition is raising, allowing protein refolding and degra-
dation of those protein aggregates wrongly appeared during stress [82].
However, this UPR process should be analyzed in report with cell, type, PS nature, PS intra-
cellular localization and PDT regimen. It is expected to launch an UPR response for those 
PS which accumulate preferentially in ER, such as hypericin. For instance, such ER-related 
oxidative stress was reported for a PDT model with sodium-porfimer photosensitizer, which 
conducts to protein polyubiquitination, carbonylation and ER lumen enlargement [65]. As a 
result, the UPR constitutively activated in tumors, as many other protection mechanisms [83], 
will protect tumor cells against anticancer therapies such as PDT [74].
2.3.2. Different effects triggered by in vitro PDT experimental models
Subtle changes triggered by photodynamic treatment are incompletely revealed, as signaling 
pathways regulate a myriad of cellular processes starting with genetic ones, such as transcrip-
tion and translation, and ending with complex cellular behavior such as proliferation, apopto-
sis, differentiation, metabolism and overall cell survival upon a certain therapeutic regimen. 
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Such finest inquiries are needed to be explored with various techniques and experimental 
models that deliver data regarding the best way of PS delivery, the best PDT regimen, cellular 
and molecular characteristics imprinted by a certain PS, therapeutical outcome and so on. 
The “practical” history of experimental PDT begun in the mid-1970s when it was discovered 
that a hematoporphyrin derivative activated with red light “cured” a mammary tumor in a 
mouse model [84]. The studies are in continuous development as an arsenal of in vitro cel-
lular models were settled for studying PDT effects on various cancers including skin cancers. 
Experimental in vitro models for PDT implying novel PS to be used in skin tumors, are related 
to cell types or types of cellular cultures (adherent, suspension, 2D or more recently 3D cel-
lular cultures). For instance, three dimensional spheroid culture cells provide very convenient 
approaches for in vitro assessment of new PS and new PDT responses and, in addition, they 
could mimic many in vivo intercellular interactions. Their convenient growth characteristics 
and exploitable features in imagistic approaches allow in vitro PDT multiple parameters stud-
ies in an “all in one” manner [85].
2.3.2.1. In vitro models for nonmelanoma skin cancer PDT therapy
Among PS tested for NMSC, hypericin a natural quinone extracted from Hypericum perfora-
tum, gain constant attention due to its good photosensitizing properties, an ideal candidate for 
PDT applied in skin tumors [86]. Hypericin as PS was currently investigated in a recent report 
where was tested in an in vitro system with human normal primary cells (keratinocytes, mela-
nocytes and fibroblasts) mimicking thus the epidermis and dermis of human skin. Fibroblasts 
were the most susceptible to hypericin-PDT, followed by melanocytes and keratinocytes in 
terms of viability. The cellular morphologies were affected by PDT for all investigated cell 
types, keratinocytes being the most unaffected even at highest PS doses. Other results indicate 
a cytoplasmic localization of hypericin in all investigated skin cell types whereas the intracel-
lular generated ROS were the most elevated in fibroblasts. This study describes the effects 
induced by in vitro PDT using hypericin on different human skin cells, gathering hence data 
on PS efficacy that could impacts in vivo application for NMSC [87].
2.3.2.2. In vitro models for melanoma PDT therapy
The main stream of the studies regarding PDT applied in melanoma encounter a major issue 
raised by this type of cancer: an evident resistance to this therapy owing to melanin that will 
compete with the PS for photons in the detriment of molecular oxygen, leading to an impaired 
phototoxicity upon target cell [47]. Therefore, the attempts regarding PDT in malignant mela-
noma have tried to combine PDT with a complementary procedure such as magneto-hyper-
thermia [88], or use an improved PS delivery system, namely a liposome formula including 
a second generation PS such as metallated phthalocyanines. This in vitro model with B16-F10 
standard cell line was used for melanoma studies [89].
Although PDT seems not to be an option in melanoma, recent publication has shown that in 
a B16-melanoma cell line and also in a B16 ectopic tumor model, ALA-SDT had been more 
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efficacious when compared to ALA-PDT. SDT is sonodynamic therapy in which the activation 
of a nontoxic sensitizer drug is performed using low-intensity ultrasound to produce cytotoxic 
ROS. SDT can activate sensitizers at a greater depth within human tissue because of the low tis-
sue attenuation of ultrasound. In PDT for melanoma the low efficacy was attributed to the dark 
pigmentation of the melanoma that filters the excitation light. In SDT, the sensitizer is activated 
by ultrasound and it is not hindered by pigmentation. These results suggest SDT as a better 
approach in comparison to PDT when treating highly pigmented cancerous skin lesions [90].
Nanocarriers for delivering one or even simultaneously two PSs [91] seem to be a good 
instrument to outcome the recognized melanoma resistance, and have been tested further 
in a mouse model of xenograft melanoma proving an increased efficacy of treatment and an 
enhanced accumulation in melanoma cell [92].
2.4. Proteomics technologies in intracellular signaling events triggered by PDT
The complex and intermingled intracellular mechanisms triggered by PDT claim high-
throughput proteomic tools to thoroughly quest the signaling events occurred in cancer cell 
followed PS activation. The cellular signaling events are first triggered by the activation of 
plasma membrane events [93]. Recently emerged, the proteomics branch focusing on these 
events is plasma membrane proteomics. From antibody-based techniques to large-scale 
“precision proteomics” centered on mass spectrometry, posttranslational modifications, 
protein-protein interactions and changes in protein expression could be analyzed by large 
scale proteomics. Proteomics in this domain is important as it conveys accurate information 
concerning (patho) physiological changes in terms of qualitative and quantitative terms of 
thousands of proteins as response to a certain antitumor therapy.
Skin cancers alterations affect specific genes and thus specific protein mediators from differ-
ent signaling pathways including the Sonic Hedgehog and NF-kB, targeting these proteins 
being the trigger for new approaches in skin cancers therapy [94].
Before tackling the proteomic involvement in PDT pattern, it must be underlined that genomic 
technologies’ advancements paved the road to molecular insights in skin cancers and related 
signaling pathways. In skin tumors, advances in sequencing techniques were driven at the 
beginning of 2000s in receptor tyrosine kinases studies, and were the tools that identified and 
indicated the presence of BRAF mutations in 50% of skin melanomas [95]. This imprints a 
major impact in development of selective BRAF inhibitors (vemurafenib and dabrafenib) trig-
gering impressive remissions in melanoma patients who benefit now from an improved treat-
ment, leading to a new era in targeted therapy [96]. Starting from this crossing-point, it could 
be further underlined that proteomics is continuing to make major progresses in biological 
processes discoveries as well as in establishing an “universal” assay platform for measuring 
proteins status and levels in any biological system subjected to different physiological milieu. 
A strength of proteomic approach is that it can translate almost in “real-time” fundamental 
science achievements into clinical practice helping in outlining personalized medicine and 
precision medicine [97].
Photosensitizers Imprinting Intracellular Signaling Pathways in Dermato-Oncology Therapy
http://dx.doi.org/10.5772/65979
15
2.4.1. Proteomic technologies in skin cancers at a glance
Proteomics includes a number of methods that could be classified depending on several crite-
ria, such as scope (for identification—quality versus measurement—quantity; discovery versus 
validation of biomarkers) and detection method (labeling versus label-free), and are broadly 
comprising spectrometry, electrophoresis and array methods. Regardless of classification cri-
teria, for analyzing PDT events, all approaches could be used to obtain important data in 
comprehending the dynamic biology of malignant transformation, tumor cell behavior and 
therapy outcome [98].
It is not the chapters’ intend to go in depth with proteomic techniques but one should keep in 
mind that there are several main stream approaches currently in use in different experimental 
sets in cancer research [97, 99] as resumed in Table 1.
The future in the proteomic domain relies in multianalyte investigation with different con-
gruent methods based on molecular characteristic evaluation such as 2-DE, MS and protein 
microarrays. As the proteomic approach is complex, so the future therapeutical approaches in 
skin cancer need the same multitargeted approach. In this aspect, photo-immune-theranostics 
reagents are the future compounds that will enter the PDT scene. This future to be therapeuti-
cal method combines molecular optical imaging, photodynamic therapy and immunotherapy 
using SNAP-tag technology which is a derivative of the O(6)-alkylguanine-DNA alkyltrans-
ferase (AGT) with the ability to efficiently conjugate to O(6)-benzylguanine (BG) molecules 
under physiological conditions depending on its folding pattern. An approach like this could 
Technology type Characteristics
Two-dimensional gel electrophoresis (2-DE) Quantitative method allowing extraction and separation in two 
dimensions (isoelectric point, molecular mass) of proteins from 
sample of interest
Mass spectroscopy (MS) Generates peptide mass fingerprints for protein detected on 2-DE; MS 
has multiple variants—electrospray ionization-liquid chromatography 
tandem mass spectroscopy (ESI-LC-MS); matrix-assisted laser 
desorption ionization time of flight (MALDI-TOF); surface-enhanced 
laser desorption ionization time of flight (SELDI-TOF); MALDI 
MS imaging (MALDI-MSI); laser capture microdissection-MS 
(LCM-MS)—optimum for extracting cells from biological specimens 
preserving the morphologies of captured cells and the nearby tissues
Protein microarray (PM) technology Proteins/antibodies/other biomolecules covalently attached to a solid 
support like glass are used to detect various interactions such as 
protein-protein, enzymatic targets, protein-small molecule (peptide, 
DNA, etc.), based on the antigen-antibody reaction; it has also many 
recent variants—cell arrays—it can analyze particular molecular 
targets expression triggered in in vivo experimental models; tissues 
array—it can analyze the molecular targets in situ across a panel of 
primary tissues in order to evaluate their clinical significance
Table 1. Main proteomic technologies applied for intracellular mechanisms investigation in skin cancer.
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simultaneously monitor and suppress the growth of skin squamous carcinoma and mela-
noma cells expressing EGFR [100].
2.4.2. Proteomic data for skin cancers
Data for cutaneous tumors were obtained from proteomic studies’ involving MS. Referring 
strictly to cutaneous cancers, ESI-LC-MS was used for investigating in paraffin-embedded 
metastatic melanomas for comparative proteomic study [101]. This method quantifies pep-
tide spectra that have been sequenced by the MS and can be used for biomarkers discovery 
through comparing the peak intensities derived from multiple LC-MS data set [102].
Biomarker identification in melanoma along with other type of cancers was also subjected of 
SELDI-TOF-MS analysis [103]. In SELDI, the protein sample mixture is spotted on a specific 
solid surface with chemical functionality such as binding affinity where some analytes in the 
samples would attach while the others will be washed off. The spotted samples on an SELDI 
surface are analyzed with TOF mass spectrometry [104].
Nevertheless, proteomic studies concerning PDT in skin tumor are still missing and are lim-
ited to in vitro approaches by assessing various cell lines. Thus a recent study published 
in 2016 involves the hexyl-aminolevulinate-mediated PDT in the human epidermoid car-
cinoma cell line A431 [105]. This analysis is another attempt to elucidate the exact trigger 
mechanisms for various death-pathways induced by PDT which are still unknown. One of 
the alteration induced by PDT via ROS is the reversible oxidation of cysteine thiols groups 
(–SH), as potential redox switch for protein activity and cellular signaling. Using MS as pro-
teomic tool, the authors found that over 2000 proteins were reversibly oxidized post-PDT, 
of which 115 of the high confidence proteins were related to the apoptotic mechanisms and 
257 have not been reported yet to be reversibly oxidized on –SH group. This study is con-
sidered the first complete mapping of reversibly oxidized proteins following PDT, among 
which ATM, p63, RSK1 p38, APE1/Ref-1 and three 14-3-3 family members represent potential 
signaling core in apoptosis death. This “core protein” furnished an apoptotic map that can 
subsequently identify potentially new redox-regulated triggers as well as potential targets 
for PDT efficacy improvement, demonstrating the benefit of proteomics in PDT [97, 105].
PM methodology is not yet a routine approach in PDT topic, although possess all strengths 
to become a robust tool in deciphering the protein-pattern of this domain. Many formats 
have been developed with whole proteomes, peptides, nucleic acids and lectins, although 
antibodies platforms remain the most popular PM surfaces. High-throughput tools in a min-
iaturized format, the arrays could perform parallel analysis, interactions and protein func-
tion on a large scale for benefit of both basic research and clinical applications [106].
Using antibody microarray, we have assessed the probable intracellular pathways by which 
PDT with aluminum-substituted disulfonated phthalocyanine trigger apoptosis in dysplas-
tic oral keratinocytes cells (DOK cell line), leading to the tumoral cells eradication. Among 
the analyzed apoptotic factors, Bcl-2, P70S6K kinase, Raf-1 and Bad proteins were the bio-
molecules whose expression changes with the greatest amplitude. Until now, the intimate 
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apoptotic mechanisms activated by PDT with metallated phthalocyanine in this type of kera-
tinocytes are still to be deciphered as well as PDT-related signaling events per se [107]. This 
complex methodology is a versatile tool allowing investigation in detail of molecular events 
related to cellular death induced by PDT.
3. Conclusion
PDT procedures have several lines of improvement in skin cancers treatment. For exam-
ple, BCC superficial lesions, preferentially located on the trunk, have the best therapeutic 
response when treated with PDT. In SCC, PDT should be combined with immune modula-
tors and chemotherapeutic agents. For melanoma, there is still a huge array of improvement 
due to its particularities and probably with the prospect of advances in gene discovery and 
translation, multidisciplinary team has to solve all the emerging issues for introducing PDT 
in melanoma.
The therapeutic future relies in the homogeneous photo-immune-theranostics reagents 
combining molecular imaging, PDT and immunotherapy. Using “next generation” pro-
teomic technologies (SNAP-tag) it would be possible to simultaneously monitor and sup-
press the growth of skin squamous carcinoma and melanoma cells expressing specific 
markers, like EGFR.
Concluding at a glance, large-scale proteomics-based signaling research will be one of the 
leaders in future photomedicine by enlarging the basic knowledge regarding (photo)therapy-
targeted networks and molecules, and by deciphering new intracellular avenues for future 
precision medicine in skin tumors. A deeper knowledge regarding signaling mechanisms in 
PDT could furnish new molecular targets and increase its clinical efficacy.
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